2005). In GCB-like DLBCL cells, IL-4 induced activation of signal transducer and activator of transcription (STAT) 6 and expression of IL-4 target genes . In contrast, in ABC-like DLBCL cells IL-4 activated Akt but did not induce the expression of IL-4 target genes nor did it induce a sustained increase in levels of nuclear phosphorylated STAT6 . The reduced activation of the Janus-activated protein kinase (JAK)-STAT6 pathway in the ABC-like cell lines was attributed to increased cytoplasmic and nuclear STAT6 dephosphorylation . We have demonstrated that two phosphatases, protein tyrosine phosphatase 1B (PTP1B) and T-cell protein tyrosine phosphatase (TCPTP), dephosphorylate cytoplasmic and nuclear STAT6 in DLBCL (Lu et al, 2007 (Lu et al, , 2008 . Protein expression levels of these phosphatases differ between the two subtypes with high expression in ABC-like DLBCL and low expression in GCBlike DLBCL, which may account for some of the differences in intracellular IL-4 signalling in the DLBCL subtypes. Whether the differences in IL-4 signalling in GCB-like and ABC-like DLBCL contribute to the differing response of these two DLBCL subtypes to chemotherapy is unknown.
This study evaluated whether IL-4 may alter the biological sensitivities of DLBCL tumours to commonly used therapeutic agents, such as doxorubicin and rituximab, which represent major components of the current standard therapy for DLBCL: R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone). We demonstrated that IL-4 distinctively modified responsiveness of the GCB-like and ABC-like DLBCL cells to these immuno-chemotherapeutic agents. IL-4 increased the sensitivity of GCB-like DLBCL to doxorubicin and rituximab chemotherapies yet protected ABC-like DLBCL from these insults. The effects of IL-4 on chemotherapy sensitivity in ABC-like DLBCL can be at least partially attributed to upregulation of Bcl-2 and the inactivation of pro-apoptotic Bad proteins. We have shown that the antiapoptotic effect of IL-4 in ABC-like DLBCL is dependent on phosphatidylinositol 3-kinase (PI3K) activation and therefore probably mediated by Akt. Since IL-4 is expressed at similar levels in both GCB-like and ABC-like DLBCL primary tumours , our observations suggest that the different clinical outcomes of patients with DLBCL subtypes may be partially attributed to IL-4-induced modulation of tumour responsiveness to chemo-immunotherapy. Furthermore, these studies suggest that addition of IL-4 to standard therapy for GCB-like DLBCL and conversely, IL-4 ablation in ABC-like DLBCL may further improve responsiveness of these tumours and warrants further investigation.
Methods

Reagents
Recombinant human IL-4 was purchased from R&D Systems (Minneapolis, MN, USA) and used in cell culture at a dose of 10 ng/ml (100 U/ml) which is similar or lower than those used in previous studies (Gee et al, 2001; Jinquan et al, 2003; Carey et al, 2007) . Doxorubicin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and rituximab was obtained from Genentech (San Francisco, CA, USA). Propidium Iodide (PI) was purchased from Invitrogen Corporation (Carlsbad, CA, USA) and 7-Amino-actinomycin D (7-AAD) was purchased from BD Pharmingen (San Diego, CA, USA). Antibodies to Bad (C-7), Mcl-1 (22) and pBad (Ser136) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to CD46, -CD55 and -CD59 and mouse IgG2a j isotype control were purchased from BD Pharmingen (San Jose, CA, USA). Bcl-2 (50-E3) antibody was purchased from Cell Signaling Technologies (Boston, MA, USA).
Cell lines and primary tumour cells and ABC-like (OCILY-3, OCILY-10) DLBCL cell lines Davis et al, 2001) were selected for this study. SUDHL-4 and SUDHL-6 cell lines were grown in RPMI 1640 medium (Fisher Scientific, Santa Clara, CA, USA) supplemented with 10% foetal calf serum, 2 nmol/l glutamine (Gibco BRL, Grand Island, NY, USA) and penicillin/streptomycin (Gibco BRL). The OCILY-3, OCILY-10 and OCILY-19 cell lines were grown in Iscove's modified Dulbecco medium (IMDM; Fisher Scientific) supplemented with 20% fresh human plasma, 2 nmol/l glutamine, penicillin/streptomycin and 50 lmol/l 2-b mercaptoethanol (Gibco BRL).
A fresh primary DLBCL tumour, obtained from a routine biopsy after the patient signed an informed consent approved by the Institutional Review Board, was used for preparation of a viable single cell suspension. The lymph node was cut sterilely and forced through a metal sieve. Mononuclear cells were obtained after centrifugation of the cell suspension over Ficoll/Hypaque gradient. B cell purification was performed by negative selection using a cocktail of biotinylated CD-2, CD-14, CD-16, CD-36, CD-43 and CD-235a (Glylcophorin A) antibodies (Miltenyi Biotec, Auburn, CA, USA). Magnetically labelled cells were separated using an autoMACS magnetic sorter (Miltenyi Biotec). Purity was assessed by anti-CD-19 (BD Biosciences, San Jose, CA, USA) staining and analysis on a Becton-Dickinson LSR analyzer (BD Biosciences). The tumour was of the GCB-like subtype, as determined by gene expression analysis and immunohistochemical studies performed as previously reported Natkunam et al, 2005 Natkunam et al, , 2008 . The primary tumour sample was cultured in RPMI 1640 medium (Fisher Scientific) supplemented with 10% foetal bovine serum, 2 nmol/l glutamine and penicillin/streptomycin and used for subsequent experiments.
Apoptosis and BCR activation studies
Cells were incubated at 10 5 cells/ml with or without IL-4 (100 U/ml), doxorubicin (25 or 100 ng/ml) and/or rituximab 
Caspase activation assay
To assay caspase activation, cells were pre-treated with IL-4 (100 U/ml) for 48 h and then treated with doxorubicin (25 ng/ml) for 24 h. Caspase-Glo 3 reagent (Promega, Madison, WI, USA) was then added to cells and luminescence was measured on a Luminoskan Ascent (Thermo Labsystems, Waltham, MA, USA) luminometer following a 30-min incubation. Readings were normalized to total amount of protein.
Colony assay
Methocult HM-4100 2AE6% methyl cellulose (StemCell Technologies, Vancouver, BC, Canada) was diluted in 20% human serum and IMDM to a final concentration of 0AE9% methyl cellulose. Cells were incubated with or without IL-4 (100 U/ml) for 48 h and doxorubicin (25 ng/ml) was added. After 36 h, aliquots of cells in medium were diluted 1/10 in 0AE9% methyl cellulose media in a 48-well format. Two weeks later colonies were counted using a 10· magnification on a CE microscope (VWR, Batavia, IL, USA).
Whole cell extract preparation and Western blot analysis
Whole human cell extracts were prepared by lysing 5 · 10 6 cells in RIPA buffer (1· PBS, 1% Nonidet P-40, 0AE5% sodium deoxycholate, 0AE1% sodium dodecyl sulphate (SDS) and 10 mmol/l phenylmethylsulfonyl fluoride, 1 lg/ml aprotinin, 100 mmol/l sodium orthovanadate) on ice for 30 min. Protein concentration in cell lysates was determined using Coomassie Protein Assay Reagent (Pierce, Rockford, IL, USA) and a Genesys 10UV Spectrophotometer (Thermo Labsystems). For Western blot analysis, 20 lg of whole cell lysates per experimental condition were separated by electrophoresis on 10% SDS-polyacrylamide gel, transferred to nitrocellulose membrane (BioRad Laboratories Inc., Hercules, CA, USA) and immunoblotted with specific antibodies.
RNA isolation, reverse transcription (RT) reaction and real-time polymerase chain reaction (PCR)
Isolation of RNA, its quantification and the RT reactions were performed as reported previously . BCL2 mRNA expression levels were measured by real time PCR using the Applied Biosystems Assays-on-Demand TM Gene Expression Product on an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Expression of the gene was normalized to RPS18 expression that was used as an endogenous RNA/cDNA quantity control, as we reported previously. Complement-dependent cytotoxicity (CDC) assay CDC assays were performed with the use of 20% human AB serum (Gemini Bio-Products, Calabasas, CA, USA) as the source of human complement. The cells were pre-incubated with IL-4 (100 U/ml) for 36 h and then treated with rituximab (50 lg/ml) for 15 min before finally adding human AB serum for one hour. Cells were then washed in PBS containing 1:20 7-AAD solution and cell viability was determined by flow cytometry on a Becton-Dickinson LSR analyzer (BD Biosciences).
Antibody-dependent cellular cytotoxicity (ADCC) assay
ADCC was performed as previously described by Wilkinson et al (2001) . Briefly, lymphoma cells were stained with PKH26 red fluorescent linker kit (Sigma-Aldrich) at 2 lmol as described by the manufacturer. Mononuclear cells were obtained by Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ, USA) centrifugation of peripheral blood from the same donor for all experiments, and were used as effector cells. 1 · 10 4 PKH26 stained target cells were incubated for 4 h at 37°C with 30· effector cells in 250 ll of RPMI medium with or without rituximab (50 lg/ml). 7-AAD dye was then added and the fraction of dead target cells was assessed by fluorescenceactivated cell sorting analysis as described by Wilkinson et al (2001) and normalized to the number of dead cells observed without addition of rituximab. The specific cell death was determined by subtracting the spontaneous cell death without antibody from that of the treated cells and then dividing the result by the maximum percentage of live cells at the beginning of the experiment.
Immunofluorescence staining of cell surface antigens
Cells (1AE0 · 10 6 ) were incubated with either isotype control or anti-human CD46, CD55 or CD59 mouse IgG2a antibodies labelled with fluorescein isothiocyanate in a total volume of 100 ll on ice for 30 min. After staining, the cells were washed three times with cold PBS supplemented with 1% bovine serum albumin. Cells were analysed by flow cytometry on a Becton-Dickinson LSR analyzer (BD Biosciences).
Statistical analysis
The two-tailed Student's t-test was used test the differences in IL-4 responses. P-values <0AE05 were considered statistically significant.
Results
IL-4 affects DLBCL response to chemotherapy
Doxorubicin is the most effective chemotherapeutic agent in the treatment of DLBCL. Treatment of GCB-like and ABClike cell lines with doxorubicin resulted in a strong induction of apoptosis and cell death in both DLBCL subtypes, and the response was dose-dependent ( Fig 1A) . We examined whether IL-4 may distinctively modulate doxorubicin-induced apoptosis and cell death in GCB-like and ABC-like DLBCL. Pre-incubation of both the GCB-and ABC-like DLBCL cell lines with IL-4 differently modified the cells' apoptotic response to doxorubicin, as assessed by staining with 7-AAD. Specifically, in the ABC-like cell lines pre-incubation with IL-4 protected cells from the doxorubicin-induced cell death while in the GCB-like cell lines, IL-4 pre-incubation augmented the doxorubicin cell killing and the difference was statistically significant (P < 0AE01) (Fig 1A and B) . Doxorubicin-induced apoptosis and cell death is associated with an activation of Caspases 3 and 7 in neoplastic lymphocytes (Gamen et al, 1997) . We therefore examined the effect of IL-4 on doxorubicin-induced activation of Caspase 3/7. In the GCB-like cell lines, as shown for SUDHL-4, pretreatment with IL-4 alone did not activate Caspase 3/7 yet Each circular mark represents a result from an independent experiment and the mean is indicated by the bar. (C) Caspase 3/7 activity was measured after incubation of cells with IL-4 (100 U/ml) for 36 h and then treatment with doxorubicin at 25 ng/ml for 36 h. Relative luciferase unit (RLU) results were normalized to amount of protein present as determined by the bicinchoninic acid protein assay as described in the Methods section.
Representative results of three independent experiments are shown. (D) Neoplastic B cells were isolated from a GCB-like DLBCL primary tumour and were incubated with IL-4 (100 U/ml) for 36 h and subsequently treated with doxorubicin at 100 ng/ml for 36 h. Cells were assayed for cell death by flow cytometry as described in the Methods section. it enhanced doxorubicin-induced Caspase 3/7 activation ( Fig 1C) . In contrast, pretreatment of the ABC-like cell lines with IL-4 decreased doxorubicin-induced activation of Caspases 3/7, as shown for OCILY-10 cells (Fig 1C) .
To demonstrate that the IL-4-induced modulation of the doxorubicin cytotoxicity was not restricted to established DLBCL cell lines, we evaluated the effects of IL-4 on a de novo untreated primary GCB-like DLBCL tumour. While stimulation of the DLBCL primary cells with IL-4 prior to doxorubicin treatment improved their viability, it also enhanced doxorubicin-mediated cell death similarly to our observations in the GCB-like cell lines.
We next utilized colony assays to determine colony formation potential in response to IL-4-doxorubicin treatment. Although previous experiments showed that IL-4 pre-treatment alone did not have a cytotoxic effect on either GCB-like and ABC-like DLBCL cell lines, it did reduce the ability of the ABC-like DLBCL cell lines to form viable colonies (Fig 2A and B) while increasing the number of colonies in the GCB-like DLBCL. These observations corroborated the observed distinct effects of IL-4 on the cell-cycle and proliferation rates of the two DLBCL subtypes previously reported . Furthermore, IL-4 differentially modulated the effects of doxorubicin on colony formation in the distinct DLBCL subtypes: it reduced the inhibitory effects of the doxorubicin on cell colony formation of ABC-like cell lines while it augmented the inhibitory effect of the doxorubicin on the colony formation of GCB-like cell lines. The observed differences were statistically significant (P < 0AE05).
(A) (B)
Fig 2. IL-4 alters ability of DLBCL cell lines treated with chemotherapy to form colonies. (A) Cells were pretreated with IL-4 (100 U/ml) for 36 h and transferred to specialized media for colony assay as described in the Methods section. Cells were then treated with doxorubicin (25 ng/ml) for 7 d, at which point colonies were counted. Pictured are individual wells prior to counting of colonies of the OCILY-10 cell line. (B) Representative results from three independent colony assay experiments in 2 ABC-like and 3 GCB-like DLBCL cell lines. *P < 0AE05; **P < 0AE01 (two-tailed Student's t-test).
IL-4 affects DLBCL cell line response to rituximab
Addition of rituximab to the standard CHOP chemotherapy was recently reported to improve outcome of DLBCL patients (Coiffier et al, 2002; Habermann et al, 2006) . Rituximab exerts its anti tumour effects via 3 mechanisms: direct cellular cytotoxicity; complement-dependent cytotoxicity (CDC); and antibody-dependent cellular cytotoxicity (ADCC). We therefore examined the effects of IL-4 on these 3 mechanisms in the different DLBCL subtypes. While IL-4 pre-treatment did not affect rituximab-mediated direct cellular cytotoxicity in either GCB-like or ABC-like cell lines (data not shown), differential effects of IL-4 were observed on rituximab-mediated CDC. In the GCB-like cell lines, pretreatment with IL-4 enhanced rituximab-mediated CDC, while in the ABC-like cell lines IL-4 protected the tumour cells (P = 0AE02, Fig 3A and B) .
Previous studies have implicated complement inhibitors as potential regulators of CDC with CD55 exhibiting this role most clearly (Golay et al, 2000) . In order to determine whether IL-4 modulated the expression of complement inhibitors that are
(C) expressed on the cell surface, we tested cell surface expression of CD46, CD55 and CD59 in unstimulated and IL-4-stimulated cells. No changes in surface expression of CD46 and CD59 were observed in both GCB-like and ABC-like cell lines (data not shown). However, in the OCILY-3 ABC-like cell line, IL-4 treatment did increase the cell surface expression of CD55 (Fig 3C) , which could contribute to the protection from cell death by rituximab. Major changes in CD55 expression were not observed the remaining DLBCL cell lines tested. Although ADCC is regarded as one of the major mechanisms by which Rituximab exerts its anti-tumour effects, no changes were observed in ADCC in the various DLBCL cell lines with IL-4 pretreatment (Fig 3D) .
IL-4 treatment modulates expression of apoptosis-regulating proteins
To assess the mechanisms by which IL-4 may modulate doxorubicin-induced apoptosis in the DLBCL subtypes, we studied the expression of several proteins that are known to regulate apoptosis. IL-4 potently induced expression of the anti-apoptotic protein Bcl-2 in the ABC-like cell lines, while its expression in the GCB-like DLBCL was unchanged (Fig 4A) . Additionally, both ABC-like cell lines exhibited consistent levels of pro-apoptotic Bad but increasing levels of pBad, the inactive form of Bad, suggesting that Bad was inactivated upon IL-4 stimulation. In contrast, all analysed GCB-like cell lines exhibited a decrease in pBad while levels of Bad remained constant or increased, leading to a net pro-apoptotic effect. No changes in levels of the Mcl-1 protein were observed in any analysed cell lines (data not shown). IL-4-induced changes in the ratio of pBad to Bad may prime the cells for apoptosis or suppress the pro-apoptotic signalling upon treatment with doxorubicin and rituximab. Similar changes in expression of apoptosis-regulating proteins were observed in DLBCL cell lines in the presence of doxorubicin (Fig 4B) .
To determine whether the changes in expression of Bcl-2 were due to the effects of IL-4 on mRNA transcription we measured BCL2 mRNA levels by real-time PCR. IL-4 treatment led to decreased BCL2 mRNA levels in one GCB-like DLBCL cell line (SUDHL-6) but significantly upregulated BCL2 mRNA transcripts in the ABC-like DLBCL cell lines (Fig 4C) . These data suggest that in ABC-like cell lines, changes in Bcl-2 protein expression may be due to IL-4-induced changes in BCL2 mRNA levels.
PI3K is necessary for IL-4 anti-apoptotic effects on ABC-like DLBCL
We previously demonstrated that IL-4 induced PI3K and Akt activation in ABC-like cell lines, but not in the GCB-like cell lines . Other studies have reported that Akt can be involved in the development of chemoresistance in DLBCL tumours (Gagnon et al, 2004; Uddin et al, 2006) . We therefore examined the effects of blocking the PI3K-Akt pathway with LY294002, a potent and specific inhibitor of PI3K, on IL-4 modulation of chemotoxicity. Pretreatment of the ABC-like cell line OCILY-10 with 5 or 10 lmol/l LY294002 reversed the protective effects of the IL-4 on doxorubicin-induced cell killing and resulted in increased cytotoxicity (Fig 5A) . LY294002 did not have any effects on doxorubicin cytotoxicity in the GCB-like DLBCL cell lines (data not shown).
Activation of GCB-like DLBCL reverses modulatory effects of IL-4
To determine whether cell activation status could change the effects of IL-4 on doxorubicin-induced apoptosis, the GCBlike cell line SUDHL-6 was treated with anti-human IgM and its effects examined on the IL-4 modification of doxorubicin cytotoxicity. B-cell receptor stimulation with anti-IgM prevented IL-4 enhancement of doxorubicin cytotoxicity in GCBlike SUDHL-6 (Fig 5B) and, in fact, IL-4 became protective for these cells. These observations suggest that B cell receptor stimulation may block and reverse IL-4-induced potentiation of doxorubicin cytotoxicity in GCB-like DLBCL cell lines.
Discussion
IL-4 plays a major role in B-cell maturation and immunological responses. IL-4 has been shown to elicit potent anti-tumour activity against carcinoma in in vitro and animal models; however, the effect of IL-4 on in vivo and in vitro behaviour of B cell lymphomas is not well understood. It has been demonstrated that IL-4 can act as a growth factor for B-lymphocytes and lymphoma cells, as follicular lymphoma cells can be grown in vitro in the CD40/stromal cell system only in the presence of IL-4. In contrast, Taylor et al (1990) reported that IL-4 inhibited growth in tissue culture of 60% of primary lymphoma specimens. Studies by Jones et al (2002) indicated that IL-4 provides growth-inhibitory signals to lymphoma cells activated through their surface Ig receptors. However, in each of these studies only one of the tumours was of DLBCL type.
We recently demonstrated that IL-4 is expressed in all analysed DLBCL tumours , and is most likely secreted by non-malignant cells, because none of the examined DLBCL cell lines expressed IL4 mRNA; however, whether the presence of IL-4 in DLBCL tumours may affect neoplastic cell sensitivity to chemotherapies has not been explored. In the present study it was observed that, while IL-4 alone did not have a significant effect on cell viability in either subtype of DLBCL, it enhanced doxorubicin-induced apoptosis and rituximab-induced CDC of GCB-like DLBCL while protecting ABC-like DLBCL cell lines and primary tumours. Although the extent of the IL-4-mediated enhancement of cell death or protection of cells from immuno-chemotherapy ranged from 10% to 50%, these seemingly small changes may translate into significant differences in patient survival rates.
Cancer cells that survive chemotherapy and have the ability to proliferate are of major importance, because these cells most likely lead to cancer relapses. Notably, patients with GCB-like and ABC-like DLBCL do not differ in their response to initial chemotherapy Lossos et al, 2004) , but do exhibit differences in overall and progression-free survival due to different relapse rates. In our studies, IL-4 blocked colony formation of GCB-like DLBCL cell lines that were treated with doxorubicin, but rescued colony formation of the ABC-like subtype after treatment with doxorubicin. In theory, IL-4-mediated preservation of malignant cells that retain the ability to proliferate following chemotherapy may predispose the patient to tumour relapse, as observed in the ABC-like DLBCL.
The expression levels of several apoptosis-regulating proteins were studied in order to determine the mechanism by which IL-4 modulates the effects of doxorubicin. IL-4 activated DLBCL cell lines were treated with IL-4 at 100 U/ml for 6-48 h. Cellular lysates were extracted at the indicated time-points and blotted for Bcl-2, Bad, pBad and actin. (B) ABC-like (OCILY-10 and OCILY-3) and GCB-like (SUDHL-4 and SUDHL-6) DLBCL cell lines were pre-treated with doxorubicin for 2 h and subsequently treated with IL-4 at 100 U/ml for 12-48 h. Cellular lysates were extracted at indicated time-points and blotted for Bcl-2, Bad, pBad and actin. (C) ABC-like (OCILY-10 and OCILY-3) and GCB-like (SUDHL-4 and SUDHL-6) DLBCL cell lines were treated with IL-4 at 100 U/ml for 6 h, RNA was extracted and BCL2 mRNA expression was measured by real-time RT-PCR. Bad phosphorylation can be mediated by Akt, which is activated in response to IL-4 in the ABC-like cell lines. We therefore examined whether prevention of Akt activation by inhibition of the upstream PI3K might reverse the protective effects of IL-4 in the ABC-like DLBCL tumours. Indeed, blocking of PI3K activity with specific inhibitor LY294002 eliminated the protective effect of the IL-4 on doxorubicin cytotoxicity in the ABC-like DLBCL, thus suggesting that the anti-apoptotic effects of IL-4 in ABC-like DLBCL cells are at least partially mediated by IL-4-induced activation of the PI3K-Akt signalling pathway in this DLBCL subtype.
IL-4 Modifies
We have previously shown that IL-4 may increase proliferation of GCB-like DLBCL cell lines, while reducing proliferation of ABC-like cell lines . Because doxorubicin is known to better target neoplastic cells that exhibit higher proliferation rates, it is possible that both the distinct effects of IL-4 on proliferation of the GCB-like and ABC-like cell lines and the observed differences in the expression of apoptosis-regulating proteins may lead to different modulation of doxorubicin cytotoxicity.
Since the gene expression profile of the ABC-like DLBCL is similar to that of normal peripheral blood lymphocytes activated via stimulation of their B-cell receptor, we examined whether IL-4 effects on the GCB-like DLBCL cells can be reversed by stimulation of B cell receptor. Indeed, stimulation of the GCB-like SUDHL-6 cells with anti-IgM altered their response to IL-4 and doxorubicin treatment, changing it to an ABC-like response manifested by reduced cytotoxicity and cell protection. The mechanism underlying this change is presently unclear. Moreover, it is unknown whether lymphoma B cell receptor is stimulated in vivo; however tonic stimulation of B cell receptor was shown to be important for survival of normal B cells (Lam et al, 1997) . If such stimulations occur in the lymphoma microenvironment, they may affect tumour sensitivity to chemotherapy.
Our studies also showed that complement-mediated cytotoxicity of rituximab in DLBCL can also be modulated by IL-4. IL-4 pretreatment enhanced complement-dependent rituximab cytotoxicity in GCB-like DLBCL while protecting ABC-like DLBCL cells from this immunotherapy. Complement inhibitors CD55 and CD59 have been suggested to alter rituximab's antitumour effects because blocking antibodies specific to CD55 or CD59 increased tumour susceptibility to rituximab-induced CDC, as reported by Golay et al (2000) . To determine whether the effects of IL-4 are mediated by these proteins, we studied the cell surface expression of complement inhibitors CD46, CD55 and CD59. Although levels of CD46 and CD59 did not change following IL-4 treatment, an upregulation of cell surface expression of CD55 was observed in the OCILY-3 ABC-like DLBCL cell line. Up-regulation of CD55 following IL-4 treatment may at least partially contribute to the observed rescue of these cells from rituximab-mediated CDC. However, the mechanism of IL-4-mediated alteration of complement-mediated cytotoxicity of rituximab in other cell lines of GCB-like and ABC-like subtypes is unknown. Overall, the role of complement in rituximab therapy remains controversial. Complement is consumed during rituximab therapy (van der Kolk et al, 2001) (A) (B) Fig 5. PI3K activation is necessary for the anti-apoptotic effects of IL-4 and stimulation of BCR in SUDHL-6 reverses effects of IL-4 on doxorubicin cytotoxicity. (A) OCILY-10 cells were treated with LY294002 at the indicated concentrations for one hour and subsequently incubated with IL-4 (100 U/ml) for 36 h. Doxorubicin (100 ng/ml) was then added and after 20 h cell viability was assayed by flow cytometry. Results represent mean and standard error (error bars) from three independent experiments. (B) SUDHL-6 cells were treated with Anti-IgM for 24 h and subsequently incubated with IL-4 (100 U/ml) for 36 h. Doxorubicin (100 ng/ml) was added and cell viability was assayed by flow cytometry at 36 h. Results represent mean and standard error (error bars) of three independent experiments. Asterisks designate level of statistical significance (*P < 0AE05; **P < 0AE01). and on some occasions, cells remaining or emerging after treatment appear to have been selected to express increased levels of complement defence molecules (Treon et al, 2001; Bannerji et al, 2003) , however it has also been shown that the expression of complement defence molecules on tumour cells does not predict patients' clinical outcome (Weng & Levy, 2001) . ADCC is considered to be the major mechanism of rituximab-induced cytotoxicity. Although ADCC has been reported to act in a complementary manner to CDC in rituximab-mediated cell death (Godal et al, 2006; van Meerten et al, 2006) we did not observe any change in rituximab ADCC with IL-4 pretreatment of cells. Although IL-4-induced upregulation of Bcl-2 protein expression was observed in the ABC-like DLBCL, it did not affect rituximab-mediated ADCC, which is concordant with the previously reported lack of Bcl-2 effects on ADCC (Godal et al, 2006) .
Overall, our observations suggest that IL-4 that is present in the tumour milieu may rescue ABC-like cells from chemotherapy-and immunotherapy-induced cell death, promoting their survival and possibly contributing to the relapses and inferior outcomes observed in these patients. Furthermore, our study demonstrates that in vitro testing of tumour sensitivity to chemotherapy may not necessarily reflect the in vivo response of the tumour, since the presence of cytokines or other substances secreted by the tumour microenvironment may alter tumour responsiveness. These interactions need to be considered when evaluating the efficacy of new therapeutic agents; equal consideration may apply for biological agents. Previously, IL-4 was used in two phase II clinical studies of relapsed non-Hodgkin lymphomas. Taylor et al (1990) reported that one of 15 patients with aggressive lymphoma demonstrated a partial response lasting longer than 15 months. In an additional study, Kurtz et al (2007) reported complete and partial responses in one and four patients, respectively, for an overall response rate of 13%. Both studies observed anti-tumour activity with IL-4, and none of them achieved the predetermined targeted response rate. However, the observed low response rates might simply reflect the nonselective enrollment of DLBCL patients whose specific lymphoma subtypes might exhibit distinct responses to this cytokine, as demonstrated in our study. In addition, in these studies IL-4 was used alone without chemotherapy and required high doses that caused side effects. It is possible that combining IL-4 at therapeutically tolerated dose levels with chemotherapy may allow potentiation of doxorubicin-induced cell killing of the GCB-like tumour cells. Selective targeting of this therapeutic approach to GCB-like DLBCL may increase the observed response rate, while opposite and non-beneficial effects may be seen for ABC-like DLBCL. Consequently, it is possible that a patient-tailored use of IL-4 or other biological or therapeutic agents based on specific tumour biology would result in higher therapeutic efficiency while eliminating the unnecessary toxicity in patients that are unlikely to respond. Further clinical studies evaluating the manipulation of IL-4 levels in DLBCL subtypes are warranted.
